BTSGU — BrightSpring Health Services, Inc. Tangible Equity Unit

Summary of BrightSpring Health Services Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $3.9 billion, up 23% year-over-year.
• Adjusted EBITDA: $206 million, a 44% increase year-over-year, with an adjusted EBITDA margin of 5.3% (up 80 basis points).
• Pharmacy Solutions Revenue: $3.4 billion, 22% growth year-over-year; adjusted EBITDA of $180 million (44% growth).
• Provider Services Revenue: $466 million, a 30% increase; adjusted EBITDA of $75 million (33% growth).
• Cash Flow from Operations: $144 million, excluding a one-time cash tax payment of $100 million related to the Community Living divestiture.
• Leverage Ratio: Reduced to 2.15x as of June 30, 2026.

2. Strategic Updates and Business Highlights

• BrightSpring is focused on delivering quality care in lower-cost settings, capitalizing on trends in U.S. healthcare.
• The company is expanding its Pharmacy Solutions, particularly in Specialty and Infusion, which saw significant growth due to new launches and strong operational performance.
• Home Health Care revenue grew by 51%, driven by acquisitions and high-quality service metrics, with nearly 95% of branches rated 4 stars or better.
• Investments in technology and automation are ongoing, with nearly 300 employees certified in Lean Sigma to improve operational efficiency.
• The company has a robust pipeline for acquisitions, focusing on tuck-ins and geographical expansions.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be between $15.1 billion and $15.425 billion, reflecting 17% to 19.5% growth.
• Adjusted EBITDA Guidance: Projected between $820 million and $845 million, indicating growth of 32.8% to 36.8%.
• The company anticipates continued growth in the second half of 2026, with cash flow from operations expected to reach approximately $600 million.

4. Bad News, Challenges, or Points of Concern

• IRA Impact: Home and Community Pharmacy expected to face a revenue impact of approximately $200 million for 2026 due to the Inflation Reduction Act (IRA), with ongoing challenges in Specialty Pharmacy projected at $175 million.
• Home and Community Pharmacy Decline: Revenue decreased by 8% year-over-year, attributed to exiting unprofitable customers and IRA impacts.
• Gross Margin Fluctuations: While gross profit per script increased year-over-year, there was a sequential decline, raising concerns about future profitability stability.
• Market Competition: The company faces competitive pressures in the fragmented Infusion market, although it remains optimistic about long-term growth.

5. Notable Q&A Insights

• Generics Contribution: The company clarified that the impact from generics like Revlimid has been stable and does not significantly alter expectations.
• Corporate Expenses: Increased corporate expenses were attributed to investments in key hires and technology initiatives.
• Infusion Business Growth: Acute infusion volumes grew over 20% year-over-year, with ongoing investments aimed at expanding chronic infusion capabilities.
• Acquisition Strategy: BrightSpring is disciplined in its M&A approach, focusing on smaller, strategic deals that enhance operational capabilities.
• Retention Metrics: High retention rates in Home and Community services are linked to investments in employee compensation, technology, and training.

Overall, BrightSpring Health Services demonstrated strong financial performance in Q2 2026, with significant growth across its segments, although it faces challenges related to regulatory impacts and market competition. The company remains optimistic about its strategic initiatives and future growth prospects.